By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Intriguing Social Unesco World Legacy Locales All over The Planet - 2Newly Identified ‘Lucy’s Hunter’ Was a 15-Foot Crocodile Lurking in Ancient Ethiopia
- 3Christopher Nolan's 'The Odyssey' trailer: See Anne Hathaway, Matt Damon and Tom Holland in 1st look at movie
- 4American tourists left stranded in the Caribbean following flight cancellations after airspace closed for Maduro operation
- 5My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs
- Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- German police 'cleared path for fascists with batons,' protesters say
- UN chief calls on Yemen's Houthi rebels to free all UN detainees
- Support Your Wellness: 20-Minute Home Exercises That Work
- Four Dead in Last Month From Animal Attacks in Nepal
- Skeleton of famed musketeer possibly found in Dutch church
- Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- Report in relation to renaming Herzog Park set to be withdrawn
- Iran war pushes Germany's deficit to 4.2% as growth outlook is cut by 50%
